BeyondSpring (BYSI) Accumulated Depreciation (2015 - 2026)
BeyondSpring (BYSI) posted Accumulated Depreciation of $660000.0 for Q1 2026, up 2.96% sequentially from $641000.0 in Q4 2025, and up 14.78% YoY from $575000.0 in Q1 2025.
BeyondSpring (BYSI) Accumulated Depreciation (2015 - 2026) Analysis & Trends
BeyondSpring has reported Accumulated Depreciation for 12 years, with the latest figure at $660000.0 in Q1 2026.
- Quarterly Accumulated Depreciation rose 14.78% year-over-year to $660000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $660000.0 (up 14.78% YoY) and the FY2025 annual result came in at $641000.0, up 15.7% from the prior year.
- Accumulated Depreciation climbed to $660000.0 in Q1 2026 per BYSI's latest filing, from $641000.0 in the prior quarter.
- Over five years, Accumulated Depreciation peaked at $660000.0 in Q1 2026 and troughed at $482000.0 in Q4 2023.
- A 5-year average of $585000.0 and a median of $586500.0 in 2025 frame the typical range for Accumulated Depreciation.
- The sharpest annual moves came in 2022 and 2023: Accumulated Depreciation surged 72.73% in 2022, then slipped 12.52% in 2023.
- Over 5 years, Accumulated Depreciation stood at $551000.0 in 2022, then retreated by 12.52% to $482000.0 in 2023, then advanced by 14.94% to $554000.0 in 2024, then rose by 15.7% to $641000.0 in 2025, then climbed by 2.96% to $660000.0 in 2026.
- According to Business Quant data, Accumulated Depreciation over the past three periods registered $660000.0, $641000.0, and $619000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | BeyondSpring | 29.85 Mn | 29.85 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 679,000.00 |
| Mar 31, 2026 | 660,000.00 |
| Dec 31, 2025 | 641,000.00 |
| Sep 30, 2025 | 619,000.00 |
| Jun 30, 2025 | 598,000.00 |
| Mar 31, 2025 | 575,000.00 |
| Dec 31, 2024 | 554,000.00 |
| Dec 31, 2023 | 482,000.00 |
| Dec 31, 2022 | 551,000.00 |
| Dec 31, 2021 | 319,000.00 |
| Sep 30, 2021 | 312,000.00 |
| Jun 30, 2021 | 295,000.00 |
| Mar 31, 2021 | 275,000.00 |
| Dec 31, 2020 | 258,000.00 |
| Sep 30, 2020 | 235,000.00 |
| Jun 30, 2020 | 213,000.00 |
| Mar 31, 2020 | 196,000.00 |
| Dec 31, 2019 | 181,000.00 |
| Sep 30, 2019 | 165,000.00 |
| Jun 30, 2019 | 145,000.00 |